Source: Google NewsPublished on 2021-02-23
Related Articles:
- The road ahead: 2021 January 25, 2021 # # # # At the start of each year, it is a useful practise to layout what is planned over the next 12 months. The events that are scheduled for the year to come, so that we can keep an eye out for them. Obviously, where 2021 will end actually is unpredictable, but an outline of what is scheduled…
- NeuroOne Medical Technologies Corporation: Announces Fiscal Third Quarter 2019 Financial Results and Provides a Corporate Update - Yahoo Finance August 14, 2019 NeuroOne Medical Technologies Corporation: Announces Fiscal Third Quarter 2019 Financial Results and Provides a Corporate Update Yahoo FinanceMINNETONKA, MN / ACCESSWIRE / August 14, 2019 / NeuroOne Medical Technologies Corporation (NMTC), a medical device company focused on the ...
- NeuroOne(TM) Medical Technologies Corporation Announces First Sale of sEEG Depth Electrode - Yahoo Finance September 23, 2019 NeuroOne(TM) Medical Technologies Corporation Announces First Sale of sEEG Depth Electrode Yahoo FinanceCompany's sEEG Electrode will be used for non-human research purposes by the Cleveland Clinic Foundation. MINNETONKA, MN / ACCESSWIRE ...
- Monthly Research Review – December 2020 December 31, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during December 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…
- NeuroOne Medical Technologies Corporation Closes $12.5 Million Private Placement with Certain Prominent Institutional Investors, Advances Towards Nasdaq Uplisting - Odessa American January 15, 2021 NeuroOne Medical Technologies Corporation Closes $12.5 Million Private Placement with Certain Prominent Institutional Investors, Advances Towards Nasdaq Uplisting Odessa American
- NeuroOne Medical Technologies Corporation Announces Private Placement | News - Southernminn.com January 12, 2021 NeuroOne Medical Technologies Corporation Announces Private Placement | News Southernminn.com
- Parkinson's Disease News - Editor's Picks (Archive 2016.11) March 17, 2017 Newsfeed: PD News PD Research News PD Fitness News PD Boxing News PD Web Articles PD Blogs PD Editor's Picks PD Twitter Newsfeed Neurons Paralyze Us During REM SleepIt will also be most useful in the study of Parkinson’s disease, since these pathologies are related. This work was published on December 12, 2016 on the website of the journal Brain.…
- Oncodesign and Servier Hit First Milestone in Developing LRRK2 Inhibitors for Parkinson’s February 19, 2020 Oncodesign and Servier have reached the first key milestone months ahead of schedule in their partnership to develop LRRK2 inhibitors for Parkinson’s disease, the companies announced in a press release. “The collaboration works perfectly and both teams are up to the challenges,” said Philippe Genne, PhD, Oncodesign’s founder and CEO. “The results were obtained sooner than expected which allowed us…
- Oncodesign and Servier Hit First Milestone in Developing LRRK2 Inhibitors for Parkinson’s February 19, 2020 Oncodesign and Servier have reached the first key milestone months ahead of schedule in their partnership to develop LRRK2 inhibitors for Parkinson’s disease, the companies announced in a press release. “The collaboration works perfectly and both teams are up to the challenges,” said Philippe Genne, PhD, Oncodesign’s founder and CEO. “The results were obtained sooner than expected which allowed us…
- Oncodesign and Servier Hit First Milestone in Developing LRRK2 Inhibitors for Parkinson’s February 19, 2020 Oncodesign and Servier have reached the first key milestone months ahead of schedule in their partnership to develop LRRK2 inhibitors for Parkinson’s disease, the companies announced in a press release. “The collaboration works perfectly and both teams are up to the challenges,” said Philippe Genne, PhD, Oncodesign’s founder and CEO. “The results were obtained sooner than expected which allowed us…
- The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
- NeuroOne Medical Technologies Corporation Appoints Ronald McClurg, Experienced Financial Industry Executive, as Chief Financial Officer - Southernminn.com January 7, 2021 NeuroOne Medical Technologies Corporation Appoints Ronald McClurg, Experienced Financial Industry Executive, as Chief Financial Officer Southernminn.com
- Monthly Research Review – January 2021 January 31, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during the previous 4 weeks. The post is divided into eight parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical…
- Mitsubishi Tanabe Pharma Corporation Group Announces Presentation of Patient-Reported Results from Phase 2 ND0612 Study at International Congress of Parkinson's Disease and Movement Disorders - BioSpace September 23, 2019 Mitsubishi Tanabe Pharma Corporation Group Announces Presentation of Patient-Reported Results from Phase 2 ND0612 Study at International Congress of Parkinson's Disease and Movement Disorders BioSpaceJERSEY CITY, N.J., Sept. 23, 2019 /PRNewswire/ -- Mitsubishi Tanabe Pharma Corporation Group announced today the presentation of an analysis of ...
- NeuroOne Medical appoints new CFO - Mass Device January 7, 2021 NeuroOne Medical appoints new CFO Mass Device
- Inhibikase Therapeutics Announces Partnership with Clintrex Research Corporation; C. Warren Olanow, MD, to Serve as Interim Chief Medical Officer - BioSpace January 4, 2021 Inhibikase Therapeutics Announces Partnership with Clintrex Research Corporation; C. Warren Olanow, MD, to Serve as Interim Chief Medical Officer BioSpace
- Global Internal Neuromodulation Device Market Size, Share, Growth, Product Type, Industry Trends & Forecast to 2024: Medtronic, Boston Scientific Corporation, St. Jude Medical, Nevro Corporation, Cyberonics - StockNewsMagazine May 27, 2019 Global Internal Neuromodulation Device Market Size, Share, Growth, Product Type, Industry Trends & Forecast to 2024: Medtronic, Boston Scientific Corporation, St. Jude Medical, Nevro Corporation, Cyberonics StockNewsMagazineThe following Internal Neuromodulation Device market report is a study of the Healthcare industry. The report is an encapsulation of all the data a new player ...
- Longevity Acquisition Corporation Announces 4D pharma Joining Landmark Parkinson's Progression Markers Initiative - BioSpace December 21, 2020 Longevity Acquisition Corporation Announces 4D pharma Joining Landmark Parkinson's Progression Markers Initiative BioSpace
- Cross-platform comparison of highly sensitive immunoassay technologies for cytokine markers: Platform performance in post-traumatic stress disorder and Parkinson's disease. February 20, 2021 Related ArticlesCross-platform comparison of highly sensitive immunoassay technologies for cytokine markers: Platform performance in post-traumatic stress disorder and Parkinson's disease. Cytokine X. 2020 Jun;2(2):100027 Authors: Lasseter HC, Provost AC, Chaby LE, Daskalakis NP, Haas M, Jeromin A Abstract There is mounting evidence of systemic inflammation in post-traumatic stress disorder (PTSD) and Parkinson's disease (PD), yet inconsistency and a lack of…
- Q-State Biosciences Announces Achievement of Key Research Milestone with Chamishi Therapeutics - BioSpace February 8, 2021 Q-State Biosciences Announces Achievement of Key Research Milestone with Chamishi Therapeutics BioSpace
- Abbott Partners with NIH on BRAIN Initiative to Use Neuromodulation Technologies May 16, 2019 Abbott is partnering with the National Institutes of Health (NIH) to explore the use of its neuromodulation technologies for treating chronic pain and progressive movement disorders, including Parkinson’s disease. The partnership’s goal is to drive forward the Brain Research through Advancing Innovative Neurotechnologies initiative, known as BRAIN, which is working to accelerate neuroscience research. With this collaboration agreement, Abbott will…
- Monthly research review: February 2020 February 29, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during February 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…